The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2025 | Deep learning CT biomarker predicts OS in advanced NSCLC
Ronan Joseph Kelly, MD, Charles A. Sammons Cancer Center at Baylor University Medical Center, Dallas, TX, describes the validation of serialCTRS, a deep learning-derived biomarker that evaluates thoracic CT changes to predict overall survival (OS) in advanced non-small cell lung cancer (NSCLC). Data from a clinical trial and a real-world dataset, serialCTRS outperformed RECIST 1.1 in prognostic accuracy. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
